Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07089706 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations
A Phase 4 study of COVID-19, sponsored by ModernaTX.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 832
- Enrollment target
- 5
- Study locations
NCT07089706 is a Phase 4 study of COVID-19 that is actively recruiting participants, run by ModernaTX. The registered enrollment target is 832 participants, below the 55,210-participant average among 203 other COVID-19 trials with a reported enrollment target (98% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT07089706, a Phase 4 study of COVID-19, is actively recruiting participants, sponsored by ModernaTX.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 832 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to evaluate the immunogenicity and safety of the recommended variant-containing formulations of mRNA-1283 COVID-19 vaccine (mNEXSPIKE®) within the current epidemiological environment.
Conditions Studied
Interventions
- BIOLOGICAL mRNA-1283.251 Variant-containing Formulation
Study Locations (5)
Louisiana
- DelRicht Research-Baton Rouge - Baton Rouge
- DelRicht Research-New Orleans - New Orleans
Georgia
- DelRicht Research-Atlanta - Atlanta
Mississippi
- DelRicht Research-Gulfport - Gulfport
Oklahoma
- DelRicht Research-Tulsa - Tulsa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 832 participants |
| Start Date | 2025-07-21 |
| Est. Completion | 2026-05-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07089706
The ClinicalTrials.gov registry entry for NCT07089706 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 832 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,210-participant average among 203 other COVID-19 trials with a reported enrollment target (98% lower). The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which mRNA-1283.251 Variant-containing Formulation is the first listed.
NCT07089706 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Louisiana, Georgia, Mississippi.
Frequently Asked Questions
What is clinical trial NCT07089706 about?
NCT07089706 is a clinical study titled "A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations". The purpose of this study is to evaluate the immunogenicity and safety of the recommended variant-containing formulations of mRNA-1283 COVID-19 vaccine (mNEXSPIKE®) within the current epidemiological environment.
What is the current status of trial NCT07089706?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 832 participants. The study started on 2025-07-21. Estimated completion is 2026-05-11.
What conditions does trial NCT07089706 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT07089706?
The interventions under investigation include: mRNA-1283.251 Variant-containing Formulation (BIOLOGICAL).
Who is sponsoring clinical trial NCT07089706?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07089706 being conducted?
This trial has 5 study locations across Georgia, Louisiana, Mississippi, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Pilot Clinical Evaluation of Astepro® Nasal Spray for Management of Early SARS-CoV-2 Infection
RECRUITING · Phase 4
-
Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients
RECRUITING · Phase 4
-
Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
RECRUITING · Phase 4
-
COVID-19 Reactogenicity
ACTIVE NOT RECRUITING · Phase 4
-
Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States
ACTIVE NOT RECRUITING · Phase 4
-
Vitamin D Supplementation in the Prevention and Mitigation of COVID-19 Infection
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.